The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers

Losartan is an angiotensin II receptor antagonist that is metabolized by CYP2C9 and CYP3A4 to a more potent antihypertensive metabolite, E3174. Interaction studies with inhibitors of CYP3A4 have not demonstrated significant changes in the pharmacokinetics of losartan or E3174. The authors assessed the steady-state pharmacokinetics of losartan and E3174 when administered alone and concomitantly with fluvastatin, a specific CYP2C9 inhibitor. A prospective, open-label, crossover study was conducted in 12 healthy volunteers with losartan alone and in combination with fluvastatin. The baseline phase was 7 days of losartan (50 mg QAM), and the inhibition phase was 14 total days of fluvastatin (40 mg QHS), with the final 7 days including losartan. The authors found that fluvastatin did not significantly change the steady-state AUC0-24 or half-life of losartan or E3174. Losartan apparent oral clearance was not affected by fluvastatin. Inhibition of losartan metabolism appears to require both CYP2C9 and CYP3A4 inhibition.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Wang, C.-Q. Xiao, Z. Li, D. Guo, Y. Chen, L. Fan, R.-H. Qian, X.-J. Peng, D.-L. Hu, and H.-H. Zhou Effect of Soy Extract Administration on Losartan Pharmacokinetics in Healthy Female Volunteers Ann. Pharmacother., June 1, 2009; 43(6): 1045 - 1049. [Abstract] [Full Text] [PDF]

				U. Yasar, G. Tybring, M. Hidestrand, M. Oscarson, M. Ingelman-Sundberg, M.-L. Dahl, and E. Eliasson Role of CYP2C9 Polymorphism in Losartan Oxidation Drug Metab. Dispos., July 1, 2001; 29(7): 1051 - 1056. [Abstract] [Full Text] [PDF]